Find Research Outputs

Search in all content

Filters for Research Output

Search concepts
Selected Filters

Publication Year

  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011

Author

  • Eric J Lawitz
2020

Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients with Type-2 Diabetes with Biopsy-proven Nonalcoholic Fatty Liver Disease

Singh, A., Gosai, F., Siddiqui, M. T., Gupta, M., Lopez, R., Lawitz, E., Poordad, F., Carey, W., McCullough, A. & Alkhouri, N., Jan 1 2020, (Accepted/In press) In : Journal of Clinical Gastroenterology.

Research output: Contribution to journalArticle

2 Scopus citations

Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials

Brown, A., Welzel, T. M., Conway, B., Negro, F., Bräu, N., Grebely, J., Puoti, M., Aghemo, A., Kleine, H., Pugatch, D., Mensa, F. J., Chen, Y. J., Lei, Y., Lawitz, E. & Asselah, T., Apr 1 2020, In : Liver International. 40, 4, p. 778-786 9 p.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension

The Belapectin (GR-MD-02) Study Investigators, Apr 2020, In : Gastroenterology. 158, 5, p. 1334-1345.e5

Research output: Contribution to journalArticle

Open Access
7 Scopus citations
4 Scopus citations

Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection

Younossi, Z. M., Stepanova, M., Racila, A., Afendy, A., Lawitz, E. J., Schwabe, C., Ruane, P. J., Lalezari, J., Reddy, K. R., Jacobson, I. M., Muir, A. J., Gaggar, A., Myers, R. P., Younossi, I. & Nader, F., Feb 2020, In : Clinical Gastroenterology and Hepatology. 18, 2, p. 468-476.e11

Research output: Contribution to journalArticle

1 Scopus citations

Not Achieving Sustained Viral Eradication of Hepatitis C Virus after Treatment Leads to Worsening Patient-reported Outcomes

Younossi, Z. M., Stepanova, M., Jacobson, I., Muir, A. J., Pol, S., Zeuzem, S., Younes, Z., Herring, R., Lawitz, E., Younossi, I. & Racila, A., Feb 3 2020, In : Clinical Infectious Diseases. 70, 4, p. 628-632 5 p.

Research output: Contribution to journalArticle

Open Access
3 Scopus citations

Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension

IDN-6556-14 Investigators , May 2020, In : Journal of Hepatology. 72, 5, p. 885-895 11 p.

Research output: Contribution to journalArticle

4 Scopus citations

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

STELLAR-3 and STELLAR-4 Investigators, Jul 2020, In : Journal of Hepatology. 73, 1, p. 26-39 14 p.

Research output: Contribution to journalArticle

8 Scopus citations

Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study

Lawitz, E., Poordad, F., Gutierrez, J. A., Beumont, M., Beets, G., Vandevoorde, A., Remoortere, P. V., Luo, D., Vijgen, L., Eygen, V. V. & Gamil, M., Jun 1 2020, In : Health Science Reports. 3, 2, e145.

Research output: Contribution to journalArticle

Open Access
2019

Characteristics and outcomes of liver transplantation for primary biliary cholangitis in young patients: Analysis of the united network for organ sharing database

Singh, A., Fritze, D., Mansouri, M., Lopez, R., Poordad, F., Lawitz, E., Cigarroa, F., Halff, G. & Alkhouri, N., Jun 1 2019, In : Transplantation. 103, 6, p. 1191-1198 8 p.

Research output: Contribution to journalArticle

1 Scopus citations

Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort

Khoudari, G., Singh, A., Noureddin, M., Fritze, D., Lopez, R., Asaad, I., Lawitz, E., Poordad, F., Kowdley, K. V. & Alkhouri, N., Jan 1 2019, In : World Journal of Hepatology. 11, 10, p. 710-718 9 p.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients

Pockros, P. J., Fuchs, M., Freilich, B., Schiff, E., Kohli, A., Lawitz, E. J., Hellstern, P. A., Owens-Grillo, J., Van Biene, C., Shringarpure, R., MacConell, L., Shapiro, D. & Cohen, D. E., Nov 1 2019, In : Liver International. 39, 11, p. 2082-2093 12 p.

Research output: Contribution to journalArticle

16 Scopus citations
1 Scopus citations

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

Lawitz, E., Flisiak, R., Abunimeh, M., Sise, M. E., Park, J. Y., Kaskas, M., Bruchfeld, A., Wörns, M. A., Aglitti, A., Zamor, P. J., Xue, Z., Schnell, G., Jalundhwala, Y. J., Porcalla, A., Mensa, F. J. & Persico, M., 2019, (Accepted/In press) In : Liver International.

Research output: Contribution to journalArticle

2 Scopus citations

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease

Lawitz, E., Gane, E., Cohen, E., Vierling, J., Agarwal, K., Hassanein, T., Mantry, P. S., Pockros, P. J., Bennett, M., Kemmer, N., Morelli, G., Zha, J., Wang, D., Shulman, N. S., Cohen, D. E. & Reddy, K. R., Feb 2019, In : Kidney International Reports. 4, 2, p. 257-266 10 p.

Research output: Contribution to journalArticle

Open Access
5 Scopus citations

Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection

Lawitz, E., Poordad, F., Anderson, L. J., Vesay, M., Kelly, M. M., Liu, H., Gao, W., Fernsler, D., Asante-Appiah, E., Robertson, M. N., Hanna, G. J., Barr, E., Butterton, J., Kowdley, K. V., Hassanein, T., Sahota, A., Gordon, S. C. & Yeh, W. W., Jun 2019, In : Journal of Viral Hepatitis. 26, 6, p. 675-684 10 p.

Research output: Contribution to journalArticle

2 Scopus citations

Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib

Jayakumar, S., Middleton, M. S., Lawitz, E. J., Mantry, P. S., Caldwell, S. H., Arnold, H., Mae Diehl, A., Ghalib, R., Elkhashab, M., Abdelmalek, M. F., Kowdley, K. V., Stephen Djedjos, C., Xu, R., Han, L., Mani Subramanian, G., Myers, R. P., Goodman, Z. D., Afdhal, N. H., Charlton, M. R., Sirlin, C. B. & 1 others, Loomba, R., Jan 2019, In : Journal of Hepatology. 70, 1, p. 133-141 9 p.

Research output: Contribution to journalArticle

Open Access
33 Scopus citations

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials

Anstee, Q. M., Lawitz, E. J., Alkhouri, N., Wong, V. W. S., Romero-Gomez, M., Okanoue, T., Trauner, M., Kersey, K., Li, G., Han, L., Jia, C., Wang, L., Chen, G., Subramanian, G. M., Myers, R. P., Djedjos, C. S., Kohli, A., Bzowej, N., Younes, Z., Sarin, S. & 5 others, Shiffman, M. L., Harrison, S. A., Afdhal, N. H., Goodman, Z. & Younossi, Z. M., Nov 1 2019, In : Hepatology. 70, 5, p. 1521-1530 10 p.

Research output: Contribution to journalArticle

20 Scopus citations

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

REGENERATE Study Investigators, Dec 14 2019, In : The Lancet. 394, 10215, p. 2184-2196 13 p.

Research output: Contribution to journalArticle

49 Scopus citations

Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients

Loo, N., Lawitz, E., Alkhouri, N., Wells, J., Landaverde, C., Coste, A., Salcido, R., Scott, M. & Poordad, F., Jan 1 2019, In : World Journal of Gastroenterology. 25, 18, p. 2229-2239 11 p.

Research output: Contribution to journalArticle

Open Access

Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life

Younossi, Z. M., Stepanova, M., Lawitz, E. J., Reddy, K. R., Wai-Sun Wong, V., Mangia, A., Muir, A. J., Jacobson, I., Djedjos, C. S., Gaggar, A., Myers, R. P., Younossi, I., Nader, F. & Racila, A., Oct 1 2019, In : The American journal of gastroenterology. 114, 10, p. 1636-1641 6 p.

Research output: Contribution to journalArticle

1 Scopus citations

Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment

Kosloski, M. P., Wang, H., Pugatch, D., Mensa, F. J., Gane, E., Lawitz, E., Marbury, T. C., Preston, R. A., Kort, J. & Liu, W., Feb 6 2019, In : European Journal of Clinical Pharmacology. 75, 2, p. 217-226 10 p.

Research output: Contribution to journalArticle

3 Scopus citations

Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance

Loo, N., Hanysak, B., Mann, J., Ramirez, R., Kim, J., Mitchell, R., Van Frank, T., Guerrero, R., Hinojosa, K., Christensen, K., Pedicone, L. D., Alkhouri, N., Wells, J., Landaverde, C., Rodas, F., Lawitz, E. & Poordad, F., Jun 1 2019, In : Medicine. 98, 26, p. e16254

Research output: Contribution to journalArticle

Open Access
2 Scopus citations

Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis

Younossi, Z. M., Stepanova, M., Anstee, Q. M., Lawitz, E. J., Wai-Sun Wong, V., Romero-Gomez, M., Kersey, K., Li, G., Subramanian, G. M., Myers, R. P., Djedjos, C. S., Okanoue, T., Trauner, M., Goodman, Z. & Harrison, S. A., Nov 2019, In : Clinical Gastroenterology and Hepatology. 17, 12, p. 2552-2560.e10

Research output: Contribution to journalArticle

Open Access
7 Scopus citations
2018

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

Zoulim, F., Moreno, C., Lee, S. S., Buggisch, P., Horban, A., Lawitz, E., Corbett, C., Lenz, O., Fevery, B., Verbinnen, T., Shukla, U. & Jessner, W., Jan 30 2018, In : Virology Journal. 15, 1, 26.

Research output: Contribution to journalArticle

Open Access
2 Scopus citations

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis

Lawitz, E. J., Coste, A., Poordad, F., Alkhouri, N., Loo, N., McColgan, B. J., Tarrant, J. M., Nguyen, T., Han, L., Chung, C., Ray, A. S., McHutchison, J. G., Subramanian, G. M., Myers, R. P., Middleton, M. S., Sirlin, C., Loomba, R., Nyangau, E., Fitch, M., Li, K. & 1 others, Hellerstein, M., Dec 2018, In : Clinical Gastroenterology and Hepatology. 16, 12, p. 1983-1991.e3

Research output: Contribution to journalArticle

43 Scopus citations

Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor

Lawitz, E., Yang, J. C., Stamm, L. M., Taylor, J. G., Cheng, G., Brainard, D. M., Miller, M. D., Mo, H. & Dvory-Sobol, H., Jan 1 2018, In : Antiviral Therapy. 23, 4, p. 325-334 10 p.

Research output: Contribution to journalArticle

15 Scopus citations

Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis (PLoS ONE (2018) 13:8 (e0202226) DOI: 10.1371/journal.pone.0202226)

Alkhouri, N., Johnson, C., Adams, L., Kitajima, S., Tsuruno, C., Colpitts, T. L., Hatcho, K., Lawitz, E., Lopez, R. & Feldstein, A. E., Oct 2018, In : PloS one. 13, 10, e0205541.

Research output: Contribution to journalComment/debate

Open Access

DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis

Loomba, R., Gindin, Y., Jiang, Z., Lawitz, E., Caldwell, S., Djedjos, C. S., Xu, R., Chung, C., Myers, R. P., Subramanian, G. M., Goodman, Z., Charlton, M., Afdhal, N. H. & Diehl, A. M., Jan 25 2018, In : JCI Insight. 3, 2

Research output: Contribution to journalArticle

Open Access
9 Scopus citations

Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection

Sulkowski, M. S., Feld, J. J., Lawitz, E., Felizarta, F., Corregidor, A. M., Khalid, O., Ghalib, R., Smith, W. B., Van Eygen, V., Luo, D., Vijgen, L., Gamil, M., Kakuda, T. N., Ouwerkerk-Mahadevan, S., Van Remoortere, P. & Beumont, M., Jun 2018, In : Journal of Viral Hepatitis. 25, 6, p. 631-639 9 p.

Research output: Contribution to journalArticle

6 Scopus citations

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

Loomba, R., Kayali, Z., Noureddin, M., Ruane, P., Lawitz, E. J., Bennett, M., Wang, L., Harting, E., Tarrant, J. M., McColgan, B. J., Chung, C., Ray, A. S., Subramanian, G. M., Myers, R. P., Middleton, M. S., Lai, M., Charlton, M. & Harrison, S. A., Nov 2018, In : Gastroenterology. 155, 5, p. 1463-1473.e6

Research output: Contribution to journalArticle

Open Access
55 Scopus citations

Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib

Younossi, Z. M., Stepanova, M., Lawitz, E., Charlton, M., Loomba, R., Myers, R. P., Subramanian, M., McHutchison, J. G. & Goodman, Z., Oct 2018, In : Liver International. 38, 10, p. 1849-1859 11 p.

Research output: Contribution to journalArticle

20 Scopus citations

Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens

Reddy, K. R., Pol, S., Thuluvath, P. J., Kumada, H., Toyota, J., Chayama, K., Levin, J., Lawitz, E. J., Gadano, A., Ghesquiere, W., Gerken, G., Brunetto, M. R., Peng, C. Y., Silva, M., Strasser, S. I., Heo, J., McPhee, F., Liu, Z., Yang, R., Linaberry, M. & 1 others, Noviello, S., May 2018, In : Liver International. 38, 5, p. 821-833 13 p.

Research output: Contribution to journalArticle

Open Access
12 Scopus citations

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

Sanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio, D., Kundu, S., Noviello, S., Luo, Y. & Christian, R., Dec 22 2018, In : The Lancet. 392, 10165, p. 2705-2717 13 p.

Research output: Contribution to journalArticle

71 Scopus citations

Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment

Mogalian, E., Brainard, D. M., Osinusi, A., Moorehead, L., Murray, B., Ling, K. H. J., Perry, R., Curtis, C., Lawitz, E., Lasseter, K., Marbury, T. & Mathias, A., Nov 1 2018, In : Clinical Pharmacokinetics. 57, 11, p. 1449-1457 9 p.

Research output: Contribution to journalArticle

4 Scopus citations

Resistance analysis of a 3-day monotherapy study with glecaprevir or pibrentasvir in patients with chronic hepatitis C virus genotype 1 infection

Ng, T. I., Pilot-Matias, T., Tripathi, R., Schnell, G., Krishnan, P., Reisch, T., Beyer, J., Dekhtyar, T., Irvin, M., Lu, L., Asatryan, A., Campbell, A., Yao, B., Lovell, S., Mensa, F., Lawitz, E. J., Kort, J. & Collins, C., Sep 2018, In : Viruses. 10, 9, 462.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis

Alkhouri, N., Johnson, C., Adams, L., Kitajima, S., Tsuruno, C., Colpitts, T. L., Hatcho, K., Lawitz, E., Lopez, R. & Feldstein, A., Aug 2018, In : PloS one. 13, 8, e0202226.

Research output: Contribution to journalArticle

Open Access
3 Scopus citations

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

GS-US-321-0105 and GS-US-321-0106 Investigators, Oct 2018, In : Gastroenterology. 155, 4, p. 1140-1153 14 p.

Research output: Contribution to journalArticle

56 Scopus citations

Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3

Younossi, Z. M., Stepanova, M., Jacobson, I. M., Asselah, T., Gane, E. J., Lawitz, E., Foster, G. R., Roberts, S. K., Thompson, A. J., Willems, B. E., Welzel, T. M., Pearlman, B., Younossi, I., Racila, A. & Henry, L., Jan 2018, In : Alimentary Pharmacology and Therapeutics. 47, 2, p. 259-267 9 p.

Research output: Contribution to journalArticle

Open Access
24 Scopus citations

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

for the GS-US-384-1497 Investigators, Feb 1 2018, In : Hepatology. 67, 2, p. 549-559 11 p.

Research output: Contribution to journalArticle

Open Access
159 Scopus citations

The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized, Multicenter Trial

Lawitz, E., Bidair, M., Marbury, T., Jones, C. T., Barve, A., Magnusson, B., Barkan, D. T., Bodendorf, U., Bracken, K., Canino, E., Chen, D., Dabovic, K., Heimbach, T., Ison, M., Jones, C. L., Kovacs, S. J., Lakshman, J. P., Li, B., Raman, P., Steiner-Swiat, R. & 4 others, Thohan, S., Wong, K. A., Zhong, W. & Colvin, R. A., Sep 2018, In : Clinical Therapeutics. 40, 9, p. 1567-1581.e4

Research output: Contribution to journalArticle

2017

Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256

Mo, H., Hedskog, C., Lawitz, E., Brainard, D. M., Yang, J., Delaney, W., Worth, A. & Miller, M. D., Apr 1 2017, In : Antiviral Research. 140, p. 151-157 7 p.

Research output: Contribution to journalArticle

3 Scopus citations

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Jacobson, I. M., Lawitz, E., Gane, E. J., Willems, B. E., Ruane, P. J., Nahass, R. G., Borgia, S. M., Shafran, S. D., Workowski, K. A., Pearlman, B., Hyland, R. H., Stamm, L. M., Svarovskaia, E., Dvory-Sobol, H., Zhu, Y., Subramanian, G. M., Brainard, D. M., McHutchison, J. G., Bräu, N., Berg, T. & 10 others, Agarwal, K., Bhandari, B. R., Davis, M., Feld, J. J., Dore, G. J., Stedman, C. A. M., Thompson, A. J., Asselah, T., Roberts, S. K. & Foster, G. R., Jul 2017, In : Gastroenterology. 153, 1, p. 113-122 10 p.

Research output: Contribution to journalArticle

133 Scopus citations

Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C

Hubbard, H. & Lawitz, E., Dec 6 2017, (Accepted/In press) In : Expert Review of Gastroenterology and Hepatology. p. 1-9 9 p.

Research output: Contribution to journalArticle

14 Scopus citations

Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment

Gane, E., Lawitz, E., Pugatch, D., Papatheodoridis, G., Bräu, N., Brown, A., Pol, S., Leroy, V., Persico, M., Moreno, C., Colombo, M., Yoshida, E. M., Nelson, D. R., Collins, C., Lei, Y., Kosloski, M. & Mensa, F. J., Oct 12 2017, In : New England Journal of Medicine. 377, 15, p. 1448-1455 8 p.

Research output: Contribution to journalArticle

183 Scopus citations

Novel treatments for chronic hepatitis C: closing the remaining gaps

Alkhouri, N., Lawitz, E. & Poordad, F., Dec 2017, In : Current Opinion in Pharmacology. 37, p. 107-111 5 p.

Research output: Contribution to journalReview article

13 Scopus citations

Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir

Wyles, D., Dvory-Sobol, H., Svarovskaia, E. S., Doehle, B. P., Martin, R., Afdhal, N. H., Kowdley, K. V., Lawitz, E., Brainard, D. M., Miller, M. D., Mo, H. & Gane, E. J., Apr 1 2017, In : Journal of Hepatology. 66, 4, p. 703-710 8 p.

Research output: Contribution to journalArticle

55 Scopus citations

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials

Lawitz, E., Buti, M., Vierling, J. M., Almasio, P. L., Bruno, S., Ruane, P. J., Hassanein, T. I., Muellhaupt, B., Pearlman, B., Jancoriene, L., Gao, W., Huang, H. C., Shepherd, A., Tannenbaum, B., Fernsler, D., Li, J. J., Grandhi, A., Liu, H., Su, F. H., Wan, S. & 9 others, Dutko, F. J., Nguyen, B. Y. T., Wahl, J., Robertson, M. N., Barr, E., Yeh, W. W., Plank, R. M., Butterton, J. R. & Yoshida, E. M., Nov 2017, In : The Lancet Gastroenterology and Hepatology. 2, 11, p. 814-823 10 p.

Research output: Contribution to journalArticle

11 Scopus citations

Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis

Jacobson, I. M., Lawitz, E., Kwo, P. Y., Hézode, C., Peng, C. Y., Howe, A. Y. M., Hwang, P., Wahl, J., Robertson, M., Barr, E. & Haber, B. A., May 2017, In : Gastroenterology. 152, 6, p. 1372-1382.e2

Research output: Contribution to journalArticle

Open Access
49 Scopus citations

Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study)

Sulkowski, M. S., Flamm, S., Kayali, Z., Lawitz, E. J., Kwo, P., McPhee, F., Torbeyns, A., Hughes, E. A., Swenson, E. S., Yin, P. D. & Linaberry, M., Jun 2017, In : Liver International. 37, 6, p. 836-842 7 p.

Research output: Contribution to journalArticle

19 Scopus citations